IMNM (Immunome, Inc.) — AI Stock Analysis & Recommendation

Research of September 7, 2026 · Healthcare / Pharmaceutical Preparations

TradeFlare's AI research teams rate IMNM a HOLD. The latest price is $18.76.

The research plan

• Entry: $26.76
• Time horizon: weeks

The current market and stock-specific conditions do not present a clear, high-conviction trading opportunity.

Why

The current market and stock-specific conditions do not present a clear, high-conviction trading opportunity. Catalysts to watch: Successful progression of Varegacestat through late-stage development; Positive clinical trial data for other pipeline assets; Favorable regulatory decisions from the FDA. Key risks: Binary risk associated with clinical trial outcomes and regulatory approvals; High cash burn rate and potential need for future capital raises; Significant historical volatility and deep drawdowns.

What could push IMNM higher

• Successful progression of Varegacestat through late-stage development.
• Positive clinical trial data for other pipeline assets.
• Favorable regulatory decisions from the FDA.

Key risks for IMNM

• Binary risk associated with clinical trial outcomes and regulatory approvals.
• High cash burn rate and potential need for future capital raises.
• Significant historical volatility and deep drawdowns.

What each AI research team found

Fundamental team: Neutral · valuation: speculative

Immunome Inc. is a speculative pre-revenue biotech company whose valuation hinges on the success of its pipeline, particularly Varegacestat. While its strong cash position and near-term catalysts offer potential upside, the inherent binary risks of drug development and the lack of current revenue create significant uncertainty. The current price is considered a speculative entry point, with the analyst consensus...

• Immunome Inc. is a pre-revenue biotechnology company with a substantial cash balance of $217.7 million, providing a runway into 2028.
• The company's valuation is driven by its pipeline, with Varegacestat in late-stage development for desmoid tumors being a key near-term catalyst with a PDUFA date of April 28, 2027.
• Despite current net losses and zero revenue, analyst consensus targets a mean of $36.31, suggesting potential upside from the current price.

Technical team: Neutral

The analysis presents conflicting signals, leading to a neutral verdict. While the scanner context hints at a potential oversold bounce, the Momentum Analyst strongly indicates bearish momentum. Volume is declining, and price is consolidating near resistance, suggesting a cautious approach with a potential for a short-term pullback.

• The stock is consolidating near resistance, with mixed signals from moving averages and recent candlestick patterns, suggesting a neutral outlook with potential for a breakout or pullback.
• The stock is trading near resistance with declining volume and a sideways price action, suggesting a neutral outlook with no clear immediate trading signal.
• Bearish momentum is confirmed by all indicators, with price trending downwards towards the support level of $24.83.

Sentiment team: Neutral

IMNM presents a neutral overall sentiment, balancing positive analyst views and pipeline developments with concerns around financial performance and recent price action. While professional analysts are largely positive, the mixed signals from news and social media, coupled with insider selling, temper conviction. The upcoming FDA decision on varegacestat remains the primary catalyst, but near-term financial...

• IMNM's news sentiment is neutral, driven by a mix of positive developments like FDA NDA acceptance and analyst 'Strong Buy' ratings, countered by concerns over recent price drops, rising losses, and a specific bearish headline, with a key catalyst being...
• Immunome (IMNM) exhibits a neutral sentiment driven by mixed news, with positive developments like FDA NDA acceptance for varegacestat and analyst 'Strong Buy' ratings countered by concerns over rising losses, dilution risk, and recent stock price...
• Immunome (IMNM) exhibits a strong positive sentiment driven by analyst consensus, significant price target upside, and positive developments in its lead candidate varegacestat, despite concerns regarding insider selling and near-term earnings.

Risk team: High

IMNM presents a HIGH overall risk profile due to its pre-revenue biotech status, characterized by significant clinical and regulatory uncertainty, substantial cash burn, and a history of deep drawdowns. The high volatility and short interest further amplify these risks, necessitating a cautious approach. Consequently, a SMALL position size is recommended with a relatively tight stop-loss to manage potential downside.

• Biotech Sector Specific Risks: As a pre-revenue biotech, IMNM faces inherent binary risks from clinical trial outcomes, regulatory approvals, and pipeline development, leading to drastic price movements.
• Deep Drawdown and High Volatility: The stock has experienced a significant drawdown of -79.66% and exhibits high annualized volatility, indicating substantial historical downside risk and potential for large price fluctuations.
• Cash Runway and Dilution Risk: With substantial negative cash flow and no revenue, IMNM faces a high risk of needing to raise capital, leading to potential shareholder dilution.

IMNM at a glance

Market value	$2.1B
Revenue growth (year over year)	-100.0%
Debt / equity	0.10

Every AI call on IMNM since May 11, 2026, and what happened next (11 calls) →

Research of September 7, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.